1887

oa SA Pharmaceutical Journal - New product focus : drug info

Volume 83, Issue 5
  • ISSN : 2221-5875

 

Abstract

Rheumalef® (leflunomide) is indicated for the treatment of adult patients with active rheumatoid arthritis (RA) as a 'disease-modifying antirheumatic drug' (DMARD) and to improve physical function.

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/mp_sapj/83/5/EJC192357
2016-01-01
2016-12-10

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error